LIVE CME WEBINAR: Friday, December 4, 2020, 7:00 PM – 8:30 PM Pacific Time (10:00 PM – 11:30 PM Eastern Time)

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Hodgkin and Non-Hodgkin Lymphoma (Part 4 of a 4-Part Series)

A Friday Satellite Symposia Live Webinar Series Preceding the 62nd ASH Annual Meeting

Faculty

Jonathan W Friedberg, MD, MMSc
Samuel E Durand Professor of Medicine
Director, James P Wilmot Cancer Institute
University of Rochester
Rochester, New York

John Kuruvilla, MD
Hematologist, Princess Margaret Cancer Centre
Associate Professor, University of Toronto
Toronto, Ontario, Canada

Ann S LaCasce, MD, MMSc
Program Director, Fellowship in Hematology/Oncology
Associate Professor of Medicine, Harvard Medical School
Institute Physician
Lymphoma Program
Dana-Farber Cancer Institute
Boston, Massachusetts



John P Leonard, MD
Richard T Silver Distinguished Professor of Hematology and Medical Oncology
Associate Dean for Clinical Research
Executive Vice Chair, Joan and Sanford I Weill Department of Medicine
Weill Cornell Medicine
New York, New York

Michael E Williams, MD, ScM
Byrd S Leavell Professor of Medicine
Chief, Hematology/Oncology Division
Physician Lead, Cancer Service Line
University of Virginia School of Medicine
Charlottesville, Virginia

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation and Seattle Genetics.

Friday, December 4, 2020
7:00 PM – 8:30 PM PT (10:00 PM – 11:30 PM ET)
Live CME-accredited webinar

Topics to Be Discussed

  • Evolving Treatment Paradigm for Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
  • Optimal Management of Follicular Lymphoma
  • Available and Emerging Approaches for Mantle Cell Lymphoma
  • Chimeric Antigen Receptor T-Cell Therapy for DLBCL and Other Lymphomas
  • Selection and Sequencing of Therapies for Patients with Hodgkin Lymphoma
A detailed agenda will be provided by November.

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of Hodgkin and non-Hodgkin lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Recall published research data and other clinical factors in the best-practice selection, sequencing or combination of available therapeutic agents in the care of patients with previously untreated or relapsed/refractory (R/R) follicular lymphoma (FL).
  • Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for the treatment of newly diagnosed and R/R mantle cell lymphoma (MCL) to determine the current and potential utility in clinical practice.
  • Incorporate new therapeutic strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma (HL).
  • Consider age, performance status and other clinical and biologic factors in up-front and subsequent therapy for patients with diffuse large B-cell lymphoma (DLBCL).
  • Develop an understanding of the biologic rationale for and appreciate the available efficacy and safety data with chimeric antigen receptor T-cell therapy, and identify patients with R/R B-cell lymphomas for whom this approach may be appropriate.
  • Design a plan of care to recognize and manage side effects and toxicities associated with current and recently approved systemic therapies in the management of FL, MCL, HL and DLBCL to support quality of life and continuation of therapy.
  • Recall new data with investigational agents and strategies demonstrating promising activity in various lymphoma subtypes, and discuss clinical trial opportunities with eligible patients.

CME Credit Form
A CME credit form will be emailed to participants within 3 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation and Seattle Genetics.